Space health nonprofit to send 6 more experiments to space on Houston company's next mission

medicine in orbit

TRISH is sending six research projects onboard Axiom Space's next mission, which is expected to launch in January. Photo via bcm.com

A Houston organization announced that it plans to launch six more experiments into space next year that look to learn more about everything from motion sickness to genome alterations during space travel.

The Translational Research Institute for Space Health, or TRISH, which is part of BCM’s Center for Space Medicine, will team up once more with Houston-based Axiom Space on its third private astronaut mission to the International Space Station, Ax-3, which is expected to launch in January. TRISH also sent experiments on Axiom's Ax-2 mission that launched in May.

The experiments are part of TRISH's Enhancing eXploration Platforms and Analog Definition (EXPAND) program, which aims "to help humans thrive on future space missions," according to a release.

“Our commercial spaceflight partners such as Axiom Space are instrumental to cutting-edge research, including these projects designed to reveal how the human body and mind function in the extreme environment of space,” Dr. Emmanuel Urquieta, TRISH chief medical officer, EXPAND program lead and assistant professor in the Center for Space Medicine at Baylor. “This work represents an important step in our journey to understand the body's response to challenging conditions, which is critical for improving human health both here on Earth and on future long-duration missions, including to the Moon and Mars.”

The six project onboard Ax-3 include:

  • Cognitive and Physiologic Responses in Commercial Space Crew on Short-Duration Missions, Mathias Basner, M.D., Ph.D., M.S., University of Pennsylvania Perelman School of Medicine: Basner’s team will track spaceflight participants’ memory, abstraction, spatial orientation, emotion recognition, risk decision-making and sustained attention before and after space travel
  • Otolith and Posture Evaluation II, Mark Shelhamer, Sc.D., Johns Hopkins University: Shelhamer's team will study how inner ears and eyes sense and respond to motion before and immediately after spaceflight to predict who is likely to develop space motion sickness.
  • Space Omics + BioBank, Richard Gibbs, Ph.D., Baylor College of Medicine: Gibbs’ team will gather biological specimens from astronauts before and after their mission to assess the effects of spaceflight on the human body at the genomic level.
  • SANS Surveillance, TRISH: The institute will study Spaceflight Associated Neuro-Ocular Syndrome by collecting vision function data during the ground phases of the mission.
  • Standardized research questionnaires, TRISH: The institute will gather contextual and qualitative data points for its EXPAND research database related to sleep, personality, health history, team dynamics and immune-related symptoms.
  • Sensorimotor adaptation, TRISH: The institute will collect data on how spaceflight participants' ability to stand, balance and have full body control.

Ax-3 is Axiom's third commercial astronaut mission to the ISS, which the company announced in March. The crew, which includes Commander Michael López-Alegría, Pilot Walter Villadei, and Mission Specialists Alper Gezeravcı and Marcus Wandt, will spend 14 days on the ISS. The mission will launch from NASA’s Kennedy Space Center in Florida aboard a SpaceX Dragon spacecraft.

Axiom also has plans for its fourth private mission, Ax-4, which it announced in August.

In addition to the partnership with Axiom, TRISH also announced late last month that it has made a new agreement with the Australian Antarctic Division's Polar Medicine Unit. The collaboration will nominate pilot projects that focus on challenges associated with extreme isolation, which have applications in long-duration space travel to the Moon and Mars.

“Our international collaboration with the AAD will extract insights to benefit all future astronauts, as well as other explorers of extreme environments,” said Dr. Dorit Donoviel, associate professor in the Center for Space Medicine at Baylor and TRISH executive director. “This agreement marks the beginning of yet another exciting venture into space health research for TRISH, and we look forward to collaborating with the AAD to advance our shared goal of promoting safe human exploration.”

In March, TRISH also announced an international agreement with the Korea National Institute of Health. The two organizations plan to collaborate on research related to mental health issues due to space travel, the challenges of food supply in deep space, the negative effects of space radiation and en-suite medical care for long-duration space travel.

TRISH is also slated to launch nine experiments on board SpaceX's Polaris Dawn mission, which is now expected to launch no earlier than 2024. The research aboard Polaris Dawn is intended to complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit.
From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston scientists develop breakthrough AI-driven process to design, decode genetic circuits

biotech breakthrough

Researchers at Rice University have developed an innovative process that uses artificial intelligence to better understand complex genetic circuits.

A study, published in the journal Nature, shows how the new technique, known as “Combining Long- and Short-range Sequencing to Investigate Genetic Complexity,” or CLASSIC, can generate and test millions of DNA designs at the same time, which, according to Rice.

The work was led by Rice’s Caleb Bashor, deputy director for the Rice Synthetic Biology Institute and member of the Ken Kennedy Institute. Bashor has been working with Kshitij Rai and Ronan O’Connell, co-first authors on the study, on the CLASSIC for over four years, according to a news release.

“Our work is the first demonstration that you can use AI for designing these circuits,” Bashor said in the release.

Genetic circuits program cells to perform specific functions. Finding the circuit that matches a desired function or performance "can be like looking for a needle in a haystack," Bashor explained. This work looked to find a solution to this long-standing challenge in synthetic biology.

First, the team developed a library of proof-of-concept genetic circuits. It then pooled the circuits and inserted them into human cells. Next, they used long-read and short-read DNA sequencing to create "a master map" that linked each circuit to how it performed.

The data was then used to train AI and machine learning models to analyze circuits and make accurate predictions for how untested circuits might perform.

“We end up with measurements for a lot of the possible designs but not all of them, and that is where building the (machine learning) model comes in,” O’Connell explained in the release. “We use the data to train a model that can understand this landscape and predict things we were not able to generate data on.”

Ultimately, the researchers believe the circuit characterization and AI-driven understanding can speed up synthetic biology, lead to faster development of biotechnology and potentially support more cell-based therapy breakthroughs by shedding new light on how gene circuits behave, according to Rice.

“We think AI/ML-driven design is the future of synthetic biology,” Bashor added in the release. “As we collect more data using CLASSIC, we can train more complex models to make predictions for how to design even more sophisticated and useful cellular biotechnology.”

The team at Rice also worked with Pankaj Mehta’s group in the department of physics at Boston University and Todd Treangen’s group in Rice’s computer science department. Research was supported by the National Institutes of Health, Office of Naval Research, the Robert J. Kleberg Jr. and Helen C. Kleberg Foundation, the American Heart Association, National Library of Medicine, the National Science Foundation, Rice’s Ken Kennedy Institute and the Rice Institute of Synthetic Biology.

James Collins, a biomedical engineer at MIT who helped establish synthetic biology as a field, added that CLASSIC is a new, defining milestone.

“Twenty-five years ago, those early circuits showed that we could program living cells, but they were built one at a time, each requiring months of tuning,” said Collins, who was one of the inventors of the toggle switch. “Bashor and colleagues have now delivered a transformative leap: CLASSIC brings high-throughput engineering to gene circuit design, allowing exploration of combinatorial spaces that were previously out of reach. Their platform doesn’t just accelerate the design-build-test-learn cycle; it redefines its scale, marking a new era of data-driven synthetic biology.”

Axiom Space wins NASA contract for fifth private mission, lands $350M in financing

ready for takeoff

Editor's note: This story has been updated to include information about Axiom's recent funding.

Axiom Space, a Houston-based space infrastructure company that’s developing the first commercial space station, has forged a deal with NASA to carry out the fifth civilian-staffed mission to the International Space Station.

Axiom Mission 5 is scheduled to launch in January 2027, at the earliest, from NASA’s Kennedy Space Center in Florida. The crew of non-government astronauts is expected to spend up to 14 days docked at the International Space Station (ISS). Various science and research activities will take place during the mission.

The crew for the upcoming mission hasn’t been announced. Previous Axiom missions were commanded by retired NASA astronauts Michael López-Alegría, the company’s chief astronaut, and Peggy Whitson, the company’s vice president of human spaceflight.

“All four previous [Axiom] missions have expanded the global community of space explorers, diversifying scientific investigations in microgravity, and providing significant insight that is benefiting the development of our next-generation space station, Axiom Station,” Jonathan Cirtain, president and CEO of Axiom, said in a news release.

As part of Axiom’s new contract with NASA, Voyager Technologies will provide payload services for Axiom’s fifth mission. Voyager, a defense, national security, and space technology company, recently announced a four-year, $24.5 million contract with NASA’s Johnson Space Center in Houston to provide mission management services for the ISS.

Axiom also announced today, Feb. 12, that it has secured $350 million in a financing round led by Type One Ventures and Qatar Investment Authority.

The company shared in a news release that the funding will support the continued development of its commercial space station, known as Axiom Station, and the production of its Axiom Extravehicular Mobility Unit (AxEMU) under its NASA spacesuit contract.

NASA awarded Axiom a contract in January 2020 to create Axiom Station. The project is currently underway.

"Axiom Space isn’t just building hardware, it’s building the backbone of humanity’s next era in orbit," Tarek Waked, Founding General Partner at Type One Ventures, said in a news release. "Their rare combination of execution, government trust, and global partnerships positions them as the clear successor-architect for life after the ISS. This is how the United States continues to lead in space.”

Houston edtech company closes oversubscribed $3M seed round

fresh funding

Houston-based edtech company TrueLeap Inc. closed an oversubscribed seed round last month.

The $3.3 million round was led by Joe Swinbank Family Limited Partnership, a venture capital firm based in Houston. Gamper Ventures, another Houston firm, also participated with additional strategic partners.

TrueLeap reports that the funding will support the large-scale rollout of its "edge AI, integrated learning systems and last-mile broadband across underserved communities."

“The last mile is where most digital transformation efforts break down,” Sandip Bordoloi, CEO and president of TrueLeap, said in a news release. “TrueLeap was built to operate where bandwidth is limited, power is unreliable, and institutions need real systems—not pilots. This round allows us to scale infrastructure that actually works on the ground.”

True Leap works to address the digital divide in education through its AI-powered education, workforce systems and digital services that are designed for underserved and low-connectivity communities.

The company has created infrastructure in Africa, India and rural America. Just this week, it announced an agreement with the City of Kinshasa in the Democratic Republic of Congo to deploy a digital twin platform for its public education system that will allow provincial leaders to manage enrollment, staffing, infrastructure and performance with live data.

“What sets TrueLeap apart is their infrastructure mindset,” Joe Swinbank, General Partner at Joe Swinbank Family Limited Partnership, added in the news release. “They are building the physical and digital rails that allow entire ecosystems to function. The convergence of edge compute, connectivity, and services makes this a compelling global infrastructure opportunity.”

TrueLeap was founded by Bordoloi and Sunny Zhang and developed out of Born Global Ventures, a Houston venture studio focused on advancing immigrant-founded technology. It closed an oversubscribed pre-seed in 2024.

View All Listings